Introduction {#Sec1}
============

Coronary heart disease (CHD) is a complex chronic inflammatory disease that is characterized by coronary artery remodeling and stenosis \[[@CR1]\]. CHD is the leading cause of mortality and disability worldwide \[[@CR2]\]. The World Health Organization reported that approximately 700,000 individuals die of CHD in China each year \[[@CR3]\]. Previous studies have suggested that age, sex, diabetes and lifestyle factors (lack of exercise, smoking or alcohol use) are associated with susceptibility to CHD. CHD is a complex and heterogeneous illness that is attributed to the interaction of environmental and genetic factors, where the genetic factors are estimated to account for 30--60% of CHD risk \[[@CR4], [@CR5]\]. However, the role of genetic/environmental interactions in the development and progression of CHD requires further clarification.

Cytochrome P450 24 subfamily A member 1 (*CYP24A1*) encodes a 24-hydroxylase for degrading the active form of vitamin D through multiple pathways \[[@CR6], [@CR7]\]. The CYP450 proteins are monooxygenases that can catalyze reactions related to drug metabolism and lipid synthesis. It has been reported that the loss of *CYP24A1* function resulted in increased serum concentration of 1,25-dihydroxyvitamin D \[[@CR7]\]. Previous studies revealed that vitamin D deficiency is a serious factor in the progression of cardiovascular disease \[[@CR8]--[@CR11]\]. In addition, *CYP24A1* polymorphisms were associated with many diseases, such as stroke, hypertension, hepatitis C virus infection and cancers. Wei Yang et al. reported that *CYP24A1* rs1570669 was linked to a reduced risk of stroke, and rs6068816 could increase susceptibility to ischemic stroke \[[@CR12]\]. Five common variants of *CYP24A1* were reportedly related to cancer risks, including prostate, breast, colon and pancreatic cancers \[[@CR13]\]. Nevertheless, the linkage between *CYP24A1* genetic variants and CHD risk in the Chinese population is not reported.

Considering the role of *CYP24A1* in multiple diseases, this study assumed that *CYP24A1* polymorphisms might be related to CHD risk. This study conducted a genetic association analysis of *CYP24A1* polymorphisms (rs2762934, rs1570669, rs6068816 and rs2296241) with CHD risk in the Chinese population.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

This study included 505 patients with CHD and 508 age- and sex-matched controls. CHD patients were recruited from Yanan University Affiliated Hospital in China. CHD patients were diagnosed as having angiographically demonstrated stenosis (≥ 50%) in one or more major coronary arteries by two experienced interventional cardiologists. The heathy controls were also collected from the Healthy Center of Yanan University Affiliated Hospital. All controls were determined to be free of cardiovascular disease. Individuals with inflammatory diseases, cardiomyopathy, renal diseases (detected by hematuria tests) or other severe diseases were excluded from this study. Characteristics of the study subjects were collected by medical records and questionnaires, including age, sex, smoking and alcohol use, duration of CHD, complications, and levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), uric acid (UA), urea, platelet (PLT), white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), triglyceride (TG) and total cholesterol (TC). The study was performed in agreement with the Ethics Committee of Yanan University Affiliated Hospital, and written informed consent was obtained from study subjects.

Single nucleotide polymorphisms (SNP) genotyping {#Sec4}
------------------------------------------------

According to the criteria of minor allele frequency (MAF) ≥ 0.05, four variants of *CYP24A1* (rs2762934, rs1570669, rs6068816 and rs2296241) were selected according to the HapMap database (<http://www.hapmap.org>). Then, blood samples were collected, and genomic DNA was extracted by a blood DNA kit (GoldMag Co. Ltd., Xi'an, China). Four variants were genotyped with the Agena MassARRAY system (Agena, San Diego, CA, USA). The primers of *CYP24A1* variants were designed by the Agena MassARRAY Assay Design 3.0 (San Diego, CA, USA; Supplementary Table [1](#MOESM1){ref-type="media"}). Agena Typer 4.0 Software (San Diego, CA, USA) was used for data management and analysis.

Data analysis {#Sec5}
-------------

SPSS 21.0 software (SPSS, Chicago, IL, USA) was applied to compute data, and the significance threshold was set at *P* \<  0.05. The variables were compared by Student's *t*-test and chi-square analysis, individually. Fisher's exact test was used to evaluate the Hardy-Weinberg equilibrium (HWE) of each SNP in healthy controls. The relationship of *CYP24A1* polymorphisms and CHD susceptibility was assessed by logistic regression after adjustment for age and sex. This study determined the differences by an odds ratio (OR) with a 95% confidence interval (CI). Haplotype analysis of *CYP24A1* polymorphisms and CHD risk was further analyzed using Haploview and PLINK software. Multifactor dimensionality reduction (MDR, version 3.0.1) was conducted to assess the impact of *CYP24A1* polymorphisms on CHD susceptibility \[[@CR14]--[@CR16]\].

Results {#Sec6}
=======

Characteristics of the study population {#Sec7}
---------------------------------------

Characteristics of the study individuals are shown in Table [1](#Tab1){ref-type="table"}. This study enrolled 505 cases and 508 controls from China. The average ages of the two groups were 62.2 ± 10.4 and 61.5 ± 8.9 years old, respectively. The distributions of age and sex were similar between the case and control groups (age: *p* = 0.609; sex: *P* = 1.000). The levels of WBC, RBC, HGB, TG and TC in the two groups had significant differences (*P* \<  0.05). Supplementary Table [2](#MOESM1){ref-type="media"} did not show significant relationships between genotypes of *CYP24A1* variants and clinical characteristics of CHD cases (*P* \> 0.05). Table 1Characteristics of the study populationVariablesCases (***n*** = 505)Controls (***n*** = 508)*P*Age, years62.2 ± 10.461.5 ± 8.90.609  \> 60280 (55%)286 (56%)  ≤ 60225 (45%)222 (44%)Sex1.000 Male334 (66%)335 (66%) Female171 (34%)173 (34%)Smoking Yes230 (46%)112 (22%) No185 (37%)153 (30%)Drinking Yes52 (10%)109 (21%) No303 (60%)98 (19%)Duration, months  ≥ 4099 (20%)  \< 40232 (46%)Hypertension Yes315 (62%) No190 (38%)HDL (mmol/L)1.10 ± 0.271.14 ± 0.230.115LDL (mmol/L)2.59 ± 0.842.60 ± 0.730.932PLT (10^9^/L)197.73 ± 59.62207.30 ± 53.920.059WBC6.89 ± 2.175.71 ± 1.41**\< 0.001**RBC4.32 ± 0.614.73 ± 0.47**\< 0.001**HGB134.31 ± 19.54144.26 ± 17.74**\< 0.001**Urea5.22 ± 2.257.50 ± 24.600.096UA (μmol/L)307.22 ± 92.67318.73 ± 84.870.146TG (mmol/L)1.55 ± 0.901.81 ± 1.65**0.022**TC (mmol/L)4.03 ± 0.965.39 ± 6.98**0.001***HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *PLT* platelet, *WBC* white blood cells, *RBC* red blood cells, *HGB* hemoglobin, *UA* uric acid, *TG* triglyceride, *TC* total cholesterolVariables are presented as the mean ± SDBold-faced values indicate significant difference (*P* \<  0.05)

Association of *CYP24A1* polymorphisms and CHD risk {#Sec8}
---------------------------------------------------

Four SNPs were genotyped in two groups, and all SNPs in the control group were HWE compliant (HWE *P* \> 0.05, Table [2](#Tab2){ref-type="table"}). For *CYP24A1* rs6068816, the frequency distribution of the T allele was higher in CHD patients than that in heathy controls (*P* = 0.014). HaploReg showed that *CYP24A1* polymorphisms were regulated by Enhancer histone marks, DNAse, motifs, proteins bound, motifs changed, NHGRI/EBI GWAS hits, SiPhy cons and Selected eQTL hits. Table [3](#Tab3){ref-type="table"} revealed that rs6068816 significantly increased CHD susceptibility in codominant (OR = 1.64, 95% CI = 1.10--2.46, *P* = 0.015), dominant (OR = 1.30, 95% CI = 1.01--1.67, *P* = 0.043), recessive (OR = 1.49, 95% CI = 1.02--2.17, *P* = 0.040) and additive (OR = 1.26, 95% CI = 1.05--1.52, *P* = 0.013) models. *CYP24A1* rs2296241 had a strong linkage with lower susceptibility to CHD (codominant: OR = 0.63, 95% CI = 0.43--0.93, *P* = 0.019; recessive: OR = 0.66, 95% CI = 0.47--0.92, *P* = 0.013 and additive: OR = 0.82, 95% CI = 0.68--0.98, *P* = 0.033). Table 2Allele frequency of *CYP24A1* SNPs and their associations with risk of CHDSNPGenotypeLocationCasesControlsMAF-CaseMAF-ControlHWE ***P***OR(95%CI)***P***HaploRegrs2762934A/G3′-UTR116/890108/9080.1150.1061.0001.10 (0.83--1.45)0.519Enhancer histone marks, DNAse, Motifs, Proteins bound, Motifs changedrs1570669A/GIntronic379/629401/6150.3760.3950.4030.92 (0.77--1.11)0.388DNAse, Proteins bound, Motifs changed, NHGRI/EBI GWAS hitsrs6068816T/CSynonymous380/622330/6800.3790.3270.9201.26 (1.05--1.51)**0.014**SiPhy cons, DNAse, Proteins bound, Motifs changed,rs2296241A/GSynonymous423/587469/5470.4190.4620.2120.84 (0.71--1.00)0.052SiPhy cons, Enhancer histone marks, DNAse, Proteins bound, Motifs changed, Selected eQTL hits*SNP* single nucleotide polymorphism, *CHD* coronary heart disease, *MAF* minor allele frequency, *OR* odds ratio, *95% CI* 95% confidence intervalBold-faced values indicate significant difference (*P* \<  0.05)Table 3Genotypes frequencies of *CYP24A1* SNPs and their associations with risk of CHDSNPGenotypeCasesControlsWithout adjustmentWith adjustmentOR(95%CI)*P*^**a**^OR(95%CI)*P*^**b**^rs2762934 co-dominantAA450.83 (0.22--3.11)0.7810.80 (0.21--3.02)0.745GA108981.14 (0.84--1.55)0.3981.13 (0.83--1.54)0.436GG39140511 dominantAA-AG1121031.13 (0.83--1.52)0.4391.11 (0.82--1.51)0.484GG39140511 recessiveAA450.81 (0.22--3.02)0.7500.78 (0.21--2.94)0.716AG-GG49950311 additive1.1 (0.83--1.46)0.5121.09 (0.82--1.44)0.563 rs1570669 co-dominantAA75740.92 (0.63--1.34)0.6550.91 (0.62--1.33)0.637GA2292530.82 (0.63--1.07)0.1460.82 (0.63--1.07)0.150GG20018111 dominantAA-AG3043270.84 (0.65--1.09)0.1840.84 (0.65--1.09)0.184GG20018111 recessiveAA75741.03 (0.72--1.45)0.8881.02 (0.72--1.44)0.914AG-GG42943411 additive0.92 (0.77--1.11)0.3860.92 (0.77--1.10)0.378rs6068816 co-dominantTT74531.63 (1.09--2.44)**0.017**1.64 (1.10--2.46)**0.015**TC2322241.21 (0.93--1.58)0.1571.21 (0.93--1.58)0.152CC19522811 dominantTT-TC3062771.29 (1.01--1.66)**0.046**1.30 (1.01--1.67)**0.043**CC19522811 recessiveTT74531.48 (1.01--2.15)**0.042**1.49 (1.02--2.17)**0.040**TC-CC42745211 additive1.26 (1.05--1.51)**0.014**1.26 (1.05--1.52)**0.013**rs2296241 co-dominantAA711010.64 (0.44--0.94)**0.023**0.63 (0.43--0.93)**0.019**GA2812670.96 (0.73--1.28)0.7950.95 (0.71--1.26)0.702GG15314011 dominantAA-AG3523680.88 (0.67--1.15)0.3370.86 (0.65--1.13)0.280GG15314011 recessiveAA711010.66 (0.47--0.92)**0.014**0.66 (0.47--0.92)**0.013**AG-GG43440711 additive0.82 (0.68--0.99)**0.041**0.82 (0.68--0.98)**0.033***SNP* single nucleotide polymorphism, *CHD* coronary heart disease, *OR* odds ratio, *95% CI* 95% confidence interval*P*^a^ values were calculated by logistic regression analysis with the comparison between CHD patients and healthy controls*P*^b^ values were calculated by logistic regression analysis with adjustment for age and genderBold-faced values indicate significant difference (*P* \<  0.05)

Furthermore, stratification analysis of *CYP24A1* polymorphisms with CHD risk was performed (Table [4](#Tab4){ref-type="table"}). In the subgroup of age ≤ 60, rs2762934 and rs6068816 significantly increased CHD risk (*P* \<  0.05). *CYP24A1* rs6068816 was also linked with higher susceptibility to CHD in the subgroup of men (homozygote: OR = 2.03, 95% CI = 1.21--3.40, *P* = 0.007; dominant: OR = 1.42, 95% CI = 1.04--1.93, *P* = 0.028; recessive: OR = 1.77, 95% CI = 1.09--2.88, *P* = 0.022; additive: OR = 1.38, 95% CI = 1.10--1.74, *P* = 0.006; allele: OR = 1.37, 95% CI = 1.09--1.72, *P* = 0.007) and smokers (homozygote: OR = 3.02, 95% CI = 1.31--6.99, *P* = 0.010; recessive: OR = 2.60, 95% CI = 1.17--5.78, *P* = 0.019; additive: OR = 1.57, 95% CI = 1.11--2.23, *P* = 0.011; allele: OR = 1.61, 95% CI = 1.15--2.27, *P* = 0.006). Rs1570669 and rs2296241 had strong relationships with CHD susceptibility in Gensini grade and male subgroups. Table 4Stratification analyses of the association of *CYP24A1* polymorphisms with susceptibility of CHDPolymorphismsSubgroupsHomozygoteHeterozygoteDominantRecessiveAdditiveAlleleOR (95%CI)*P*OR (95%CI)*P*OR (95%CI)*P*OR (95%CI)*P*OR (95%CI)*P*OR (95%CI)*P*rs2762934Age (≤ 60)----1.51 (0.93--2.44)0.0901.57 (0.97--2.53)0.060----1.61 (1.01--2.56)**0.040**1.57 (1.00--2.46)**0.048**rs1570669Gensini grade0.61 (0.31--1.20)0.1561.79 (1.06--3.02)**0.031**1.33 (0.82--2.14)0.2431.45 (0.24--0.85)**0.013**0.92 (0.66--1.29)0.6370.90 (0.64--1.26)0.544rs6068816Age (≤ 60)2.76 (1.47--5.20)**\<  0.001**1.27 (0.85--1.90)0.2501.49 (1.01--2.18)**0.040**2.42 (1.34--4.38)**\< 0.001**1.53 (1.15--2.03)**\< 0.001**1.51 (1.15--1.99)**0.003**Men2.03 (1.21--3.40)**0.007**1.30 (0.94--1.80)0.1161.42 (1.04--1.93)**0.028**1.77 (1.09--2.88)**0.022**1.38 (1.10--1.74)**0.006**1.37 (1.09--1.72)**0.007**Smoker3.02 (1.31--6.99)**0.010**1.33 (0.82--2.16)0.2511.56 (0.98--2.49)0.0602.60 (1.17--5.78)**0.019**1.57 (1.11--2.23)**0.011**1.61 (1.15--2.27)**0.006**rs2296241Men0.60 (0.37--0.96)**0.031**0.77 (0.54--1.09)0.1400.73 (0.52--1.01)0.0590.71 (0.47--1.07)0.0990.77 (0.61--0.97)**0.027**1.25 (0.16--1.90)0.180*OR* Odds ratio, *CI* Confidence interval, *CHD* coronary heart diseaseBold-faced values indicate significant difference (*P* \< 0.05)

Haplotype and MDR analysis {#Sec9}
--------------------------

The haplotype analysis of *CYP24A1* polymorphisms and CHD risk was performed, and there was no significant linkage between haplotypes and susceptibility to CHD (*P* \> 0.05). One block (rs2762934 and rs1570669) was presented in Fig. [1](#Fig1){ref-type="fig"}. In addition, the effects of SNP-SNP interactions among four SNPs in *CYP24A1* are shown in Table [5](#Tab5){ref-type="table"}. MDR analysis showed that a four-locus model, including rs2762934, rs1570669, rs6068816 and rs2296241, was the best model (cross-validation consistency = 10/10, accuracy = 0.580, *P* \<  0.001). Fig. 1Linkage disequilibrium (LD) plots containing two polymorphisms from *CYP24A1*. Block 1 includes rs2762934 and rs1570669. The numbers inside the diamonds indicate the D' for pairwise analysesTable 5MDR analysis of SNP-SNP interactionsModelTraining Bal. Acc.Testing Bal. Acc.CV ConsistencyAccuracySensitivitySpecificityOR(95%CI)*P*rs22962410.5330.53310/100.5330.6140.4521.31 (1.02--1.68)**0.035**rs1570669,rs22962410.5500.54810/100.5500.7210.3781.57 (1.20--2.05)**0.001**rs1570669,rs6068816,rs22962410.5670.5096/100.5650.4570.6731.74 (1.35--2.24)**\< 0.001**rs2762934,rs1570669,rs6068816,rs22962410.5860.48410/100.5800.6590.5011.94 (1.51--2.50)**\< 0.001***MDR* multifactor dimensionality reduction, *SNP* single nucleotide polymorphism, *CV* cross-validation, *OR* odds ratio, *CI* confidence intervalBold-faced values indicate significant difference (*P* \< 0.05)

Discussion {#Sec10}
==========

This study investigated the relationship of four *CYP24A1* SNPs (rs2762934, rs1570669, rs6068816 and rs2296241) on CHD risk; rs6068816 and rs2296241 indicated susceptibility to CHD in the Chinese Han population (*P* \<  0.05). Subgroup analysis demonstrated that rs2762934 enhanced CHD risk among younger individuals (age ≤ 60), rs2296241 decreased the risk of CHD among men, and rs6068816 was significantly linked with a higher risk of CHD in the subgroups of age ≤ 60, men, and smokers. For CHD patients, rs1570669 could enhance CHD risk in the subgroup of Gensini grade. It also showed one block (rs2762934 and rs1570669). These results might provide a new insight on the contribution of *CYP24A1* polymorphisms in CHD risk among the Chinese population.

Vitamin D is a soluble steroid hormone that plays an important role in calcium homeostasis, skeletal health and cardiovascular pathophysiology \[[@CR2]\]. It has been reported that low levels of vitamin D are linked with a variety of diseases, including diabetes, autoimmune disorders, skin diseases, cardiovascular diseases and cancers \[[@CR17]--[@CR19]\]. Vitamin D is produced in the skin and is metabolized in the liver and kidney, which requires CYP450 enzymes, such as CYP2R1, CYP27B1, CYP24A1 \[[@CR20]\]. Previous studies indicated that rs6068816 affected cancer risk through the vitamin D pathway \[[@CR21], [@CR22]\] and that rs2296241 was related to vitamin D deficiency in the development of food sensitization \[[@CR23]\]. The study mainly focused on the linkage of *CYP24A1* and CHD among the Chinese Han population. The results showed *CYP24A1* polymorphisms were associated with CHD susceptibility. *CYP24A1* rs6068816 significantly increased the risk of CHD, whereas no significant linkage of hypertension with rs6068816 and no difference in vitamin D levels among the genotypes of rs6068816 were found \[[@CR24]\]. Moreover, this study suggested that rs2296241 could protect individuals from CHD. Lu et al. also reported that rs2296241 had strong associations with systolic blood pressure (BP), diastolic BP, pulse pressure, or mean arterial pressure in the Women's Genome Healthy Study \[[@CR25]\]. These findings suggests that *CYP24A1* polymorphisms may participate in the progression of CHD, and this is likely due to the effects of *CYP24A1* on regulating the levels of vitamin D. Further studies are required to verify these results.

There are differences between the influence of age and sex on CHD; CHD more frequently occurs in men (17.6%) than women (10.6%) \[[@CR26]\]. The mortality of CHD is also different in adults between the two sexes, and it increases with age \[[@CR27]\]. However, the causes of age and sex differences in CHD are still unclear. Hence, this study evaluated the influences of *CYP24A1* polymorphisms on CHD risk in the subgroups of age and sex. The impact of rs2762934, rs6068816 and rs2296241 on CHD risk varied with age and sex. In addition, smoking was a major risk factor for CHD \[[@CR28]\]. The results showed that *CYP24A1* rs6068816 significantly increased the risk of CHD among men, smokers and subjects aged 60 years old or younger. A meta-analysis involving 20,593 cases and 25,458 controls revealed that there were no associations of rs6068816 with overall cancer risks \[[@CR13]\], but Wei Yang el al. reported that rs6068816 could enhance the susceptibility of ischemic stroke in the Chinese population \[[@CR12]\]. These studies would provide insight on the diagnosis, prevention or treatment of cardiovascular disease. Last, the study divided CHD patients into different groups according to Gensini grade, and *CYP24A1* rs1570669 could worsen the condition of patients. This finding gives us a clue as to individual treatments for CHD patients.

Study strength and limitations {#Sec11}
------------------------------

The strengths of this study were listed as following. First, the study reported the linkage of *CYP24A1* polymorphisms and CHD risk, and these impacts were related to multiple factors. Second, the association of genetic polymorphisms with CHD susceptibility was also assessed by many subgroups, as well as haplotype and MDR analysis. Third, this study used clinical data from a study population of 1013 individuals. Finally, the study provides a new candidate gene or variants for studying the subsequent pathogenesis of CHD. These findings may facilitate the diagnosis and prevention of CHD in the future.

There are some deficiencies in this study, which should be listed. First, sample size was relatively small, such that it could not give enough statistical power. Additionally, a selection bias may exist in this case-control study. Third, more risk indicators were not analyzed in the study due to limitations of information. Fourth, the study did not assay vitamin D levels in cases and controls. Finally, more studies should be performed to validate these results.

Conclusions {#Sec12}
===========

The study revealed that *CYP24A1* variants were nominally linked with CHD susceptibility, and the impacts of *CYP24A1* polymorphisms on CHD risk were related to age, sex, Gensini grade or smoking status. It suggested that *CYP24A1* variants might take part in the development of CHD. It provides a scientific basis for the underlying mechanism of CHD. In the future, these findings will guide personalized medicine for the treatment of CHD.
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**Additional file 1: Supplementary Table 1** Primers of *CYP24A1* polymorphisms**. Supplementary Table 2** Clinical characteristics of CHD patients based on *CYP24A1* polymorphisms.
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